<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approved and commonly used drugs for chronic opioid-induced constipation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approved and commonly used drugs for chronic opioid-induced constipation</h1>
<div class="graphic"><div class="figure"><div class="ttl">Approved and commonly used drugs for chronic opioid-induced constipation</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Class</td> <td class="subtitle1">Mechanism </td> <td class="subtitle1">Use</td> <td class="subtitle1">Problems</td> </tr> <tr class="divider_bottom"> <td>Bulk-forming laxatives (cellulose or psyllium seeds)</td> <td> <p>Increases mass and water content of stool</p> Decreases transit time</td> <td>Should always be considered; may be useful in changing character of the effluent from a functioning stoma</td> <td> <ul> <li>May worsen flatulence and distention </li> <li>Should be avoided in patients who are severely debilitated or suspected of early bowel obstruction </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Osmotic cathartics (magnesium salts, sodium salts, lactulose, sorbitol, polyethylene glycol)</td> <td> <p>Increases water in the bowel</p> <p>Decreases transit time</p> <p>Lactulose/sorbitol attracts water into colon, acidifies contents</p> Polyethylene glycol attracts water into the colon</td> <td> <p>Often used for bowel cleansing before medical procedures</p> <p>Lactulose and sorbitol have a slower onset and are commonly selected for long-term use; dose must be adjusted to effect</p> Polyethylene glycol is not absorbed, has a slower onset, and the powder formulation also is commonly used for long-term therapy; dose must be adjusted to effect</td> <td> <ul> <li>Severe diarrhea and dehydration may occur with overuse </li> <li>Rarely, causes serious electrolyte disorders or volume overload </li> <li>Patients with renal insufficiency or cardiac failure must be carefully monitored if sodium or magnesium salts are used </li> <li>Use of phosphate containing laxatives has been associated with acute phosphate nephropathy (rare); risk factors include chronic kidney disease, frequent use, and advanced age </li> <li>Lactulose or sorbitol may increase flatulence </li> <li>Lactulose should be avoided in patients who are lactose-intolerant </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Surfactants (docusate)</td> <td>Facilitates mixture of fat and stool</td> <td>Usually combined with a contact cathartic as a first-line therapy for opioid-induced constipation</td> <td> <ul> <li>Minimal risks </li> </ul> </td> </tr> <tr class="divider_bottom"> <td> <p>Contact cathartics diphenylmethane drugs (bisacodyl)</p> Anthraquinone drugs (cascara, senna)</td> <td> <p>Increases peristalsis</p> Reduces absorption of water and electrolytes from intraluminal contents</td> <td> <p>May be used for acute or chronic therapy</p> Often a first-line approach for long-term management, including prophylaxis when opioid therapy is initiated</td> <td> <ul> <li>Risks associated with short-term use are minimal </li> <li>"Laxative bowel," a condition characterized by dependence on laxatives for bowel function has been reported but is presumably rare </li> <li>Allergies to these substances have been reported </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Opioid antagonists</td> <td>Opioid antagonist</td> <td>Goal is "bowel withdrawal" without concurrent systemic withdrawal</td> <td> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Subcutaneous methylnaltrexone</td> <td> </td> <td>Opioid-induced constipation in refractory cases; does not cause systemic withdrawal symptoms</td> <td> <ul> <li>Methylnaltrexone must be given subcutaneously; dose adjustment needed for renal impairment </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Naloxegol</td> <td> </td> <td>Opioid-induced constipation; does not cause systemic withdrawal symptoms</td> <td> <ul> <li>Naloxegol is metabolized by CYP3A4; numerous significant drug interactions are anticipated </li> <li>Dose adjustment needed for renal impairment   </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Oral naloxone</td> <td> </td> <td>Opioid-induced constipation; parenteral formulation has been given orally, but the optimal dose and schedule are unknown</td> <td> <ul> <li>Limited evidence supporting efficacy of oral naloxone, and some patients will absorb sufficient naloxone to develop systemic withdrawal symptoms </li> <li>May cause abdominal cramping </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Fixed combination of extended-release oral oxycodone and naloxone (2:1 ratio)</td> <td> </td> <td>Chronic pain requiring around-the-clock opioid treatment and prevention or relief of opioid-induced constipation</td> <td> <ul> <li>Exceeding the maximum daily dose of 80 mg oxycodone/40 mg naloxone can cause systemic withdrawal symptoms </li> <li>Though systemic exposure of oral naloxone is low (≤3%) among patients with normal organ function, bioavailability increases in the setting of hepatic impairment and/or renal impairment </li> <li>Use is contraindicated in moderate to severe hepatic impairment </li> <li>Not recommended for perioperative use </li> </ul> </td> </tr> <tr> <td> <p>Chloride channel activator</p> Lubiprostone</td> <td>Locally acting type 2 chloride channel (ClC-2) activator</td> <td>Treatment of opioid-induced constipation</td> <td> <ul> <li>Can cause nausea and abdominal pain </li> <li>Some patients report dyspnea and/or chest tightness within 0.5-2 hours of taking the drug (mechanism unknown) </li> <li>Not studied in methadone-associated opioid-induced constipation and based upon in vitro data provided in the product label; it may not be effective for that use </li> </ul> </td> </tr> </tbody></table></div><div id="graphicVersion">Graphic 73845 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
